Date: 2017-03-16
Type of information: Nomination
Compound:
Company: Kite Pharma (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 16, 2017, Kite Pharma announced that Owen N. Witte, the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a renowned cancer researcher, has been appointed to its Board of Directors. Dr. Witte will continue to serve as Chair of Kite's Scientific Advisory Board (SAB) and will play a vital role advising the Board of Directors on the future of engineered cell therapy and synthetic biology. Dr. Witte's seminal scientific work laid the foundation for the fundamental understanding of human leukemias and epithelial cancer stem cells which propelled the development of approved targeted cancer therapies, including Gleevec® (imatinib) and Imbruvica® (ibrutinib). He will bring extensive scientific experience to the Board as Kite plans its future portfolio of chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, including allogeneic cell therapy, TCRs targeting neoantigens, and other novel TCR approaches. Dr. Witte is a member of the National Academy of Sciences , the American Academy of Arts and Sciences , and the National Academy of Medicine . In 2015, he was re-appointed by former President Barack Obama to serve for a second term on the President's Cancer Panel , which monitors the development and execution of the National Cancer Program. Dr. Witte has received many awards for his research, including most recently, in 2016, the AAMC Award for Distinguished Research in Biomedical Sciences as well as the Stanford Medical School Kornberg-Berg Lifetime Achievement Award in Biosciences.
Financial terms:
Latest news:
